Collaborative approach to oncology care

Transcript of 'Collaborative approach to oncology care'

How can collaborative relationships transform access to oncology treatments in Canada?

Having operationalized oncology patient support programs for over 20 years, Innomar has a deep level of expertise within the cancer space. When it comes to accessing specialty therapies in oncology, navigating the healthcare system in Canada can be complex and time-consuming for healthcare providers, people living with cancer, and their care partners. Collaborative relationships are a key to success.

At Innomar, our goal is to alleviate the complexity and administrative burden to support access to therapies by working closely with cancer centres and pharmaceutical manufacturers to support individuals throughout their cancer journey. It’s so important for us to have strong relationships with cancer centres. We work to understand their processes and ways of working and tailor our support to them, allowing us to show up as a united care team for individuals. We continue to focus on the need for simple access to our PSPs, for both cancer centers and those living with cancer. We also work with each centre to collaborate on where we can offset any specific demand, and to complement the care they provide.

With cancer, time is critical. We understand not only the Canadian landscape, but also the regional nuances and evolving payer requirements. Our extensive reimbursement experience can help cut down the time it takes to get approvals from payers. We build and maintain strong relationships with both public and private payer drug teams, enabling us to investigate and find solutions to challenges at the individual and organizational levels.

Our relationships with the manufacturers we work with are key. They can trust that we will leverage our expertise and connectivity with our stakeholders to continue to evolve our oncology model and remain future-forward in our thinking. We take pride in fostering collaborative relationships with oncologists, DANs/DACs, pharmaceutical manufacturers, and payers to navigate barriers that people might face when they’re dealing with a cancer diagnosis. Our ultimate goal is for each individual to receive timely access to their treatments, and we are committed to working collaboratively to support them throughout the process.